Olmedo-Martin, Raul VicenteAmo-Trillo, VictorGonzalez-Grande, RocioJimenez-Perez, Miguel2023-01-252023-01-252017-05-17Olmedo Martín RV, Amo Trillo V, González Grande R, Jiménez Pérez M. Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis. Rev Esp Enferm Dig. 2017 Sep;109(9):659-6621130-0108http://hdl.handle.net/10668/11424Vedolizumab is a humanized IgG1 monoclonal antibody that selectively blocks the lymphocyte integrin α4β7 and prevents its interaction with endothelial adhesion molecules and subsequent transmigration to the gastrointestinal tract. The drug was approved in 2014 for the induction and maintenance treatment of ulcerative colitis and moderate to severe Crohn's disease that is refractory or intolerant to conventional treatment with corticoids and immunosuppressants and/or anti-TNFα drugs. However, inflammatory bowel disease has a variable behavior following liver transplant. One third of patients with ulcerative colitis associated with primary sclerosing cholangitis are expected to deteriorate despite receiving immunosuppression to prevent rejection. There is limited experience with anti-TNFα agents in patients with inflammatory bowel disease in the setting of liver transplantation and the studies to date involve a limited number of cases. The efficacy and safety data of vedolizumab in this situation are unreliable and very preliminary. We present two cases with the aim to present the efficacy and safety of vedolizumab after one year of treatment in two patients who underwent a transplant due to primary sclerosing cholangitis. One case had de novo post-transplant ulcerative colitis refractory to two anti-TNFα drugs (golimumab and infliximab). The other patient had a colostomy due to fulminant colitis and developed severe ulcerative proctitis refractory to infliximab after reconstruction with an ileorectal anastomosis.enVedolizumabLiver transplantUlcerative colitisAdultAntibodies, Monoclonal, HumanizedCholangitis, SclerosingColitis, UlcerativeFemaleGastrointestinal AgentsHumansLiver TransplantationTreatment Outcomeresearch article28724302Restricted AccessColitis ulcerosaPreparaciones farmacéuticasTrasplante de hígadoTrasplantesEnfermedades inflamatorias del intestinoColangitis esclerosante10.17235/reed.2017.5024/2017https://doi.org/10.17235/reed.2017.5024/2017